Genovate Biotechnology Co., Ltd. (TPEX:4130)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
27.80
-0.10 (-0.36%)
Apr 29, 2026, 12:55 PM CST
40.38%
Market Cap 3.17B
Revenue (ttm) 492.41M
Net Income (ttm) 11.68M
Shares Out 113.75M
EPS (ttm) 0.10
PE Ratio 279.00
Forward PE n/a
Dividend 0.10 (0.35%)
Ex-Dividend Date Aug 20, 2025
Volume 136,411
Average Volume 1,240,062
Open 27.55
Previous Close 27.90
Day's Range 27.55 - 28.35
52-Week Range 17.65 - 40.15
Beta 0.26
RSI 30.95
Earnings Date Apr 2, 2026

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1982
Employees 190
Stock Exchange Taipei Exchange
Ticker Symbol 4130
Full Company Profile

Financial Performance

In 2025, Genovate Biotechnology's revenue was 492.41 million, a decrease of -3.61% compared to the previous year's 510.86 million. Earnings were 11.68 million, a decrease of -54.54%.

Financial Statements

News

There is no news available yet.